SCHEMBL4459522

SCHEMBL4459522

Cc1cc(Cc2ccccc2)c(O)c(C(C)(C)C)c1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 2/20 0.72
CYP2C9 P11712 2/20 0.70
CYP2C19 P33261 2/20 0.70
HIF1A Q16665 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
CYP2D6 P10635 1/20 0.62
HSD17B10 Q99714 1/20 0.62
ALDH1A1 P00352 1/20 0.53
CA2 P00918 1/20 0.53
POLB P06746 1/20 0.53
TYR P14679 1/20 0.53
BCL2 P10415 1/20 0.50
BCL2L1 Q07817 1/20 0.50
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
PTPN1 P18031 2/20 0.43
PTPN2 P17706 1/20 0.43
PTPN6 P29350 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4565241 0.94 HSPA5 (0.64) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL4456953 0.90 HSPA5 (0.59) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
Phenol SCHEMBL23706530 0.87 HSPA5 (0.77) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL8377432 0.87 HSPA5 (0.72) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
Phenol SCHEMBL10629108 0.86 CYP2C9 (0.78) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL12309162 0.86 HSPA5 (0.60) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL9817016 0.85 HSPA5 (0.60) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL9950640 0.85 HSPA5 (0.79) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL8772330 0.85 HSPA5 (0.79) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL12309158 0.85 HSPA5 (0.79) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3993782-A ALKYL-2-BENZYL-PHENOLS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1976-11-23 US claimed
US-9260358-B2 Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains a phenoxy ligand that is functionalized by a heteroatom IFP Energies Nouvelles (FR) 2016-02-16 US disclosed
US-9260358-B2 Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains a phenoxy ligand that is functionalized by a heteroatom IFP Energies Nouvelles (FR) 2016-02-16 US disclosed
US-20110213190-A1 PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM IFP (FR) 2011-09-01 US disclosed
US-20110213190-A1 PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM IFP (FR) 2011-09-01 US disclosed
US-7622247-B2 Protective overcoats for thermally developable materials CARESTREAM HEALTH, INC. (US) 2009-11-24 US disclosed
US-20090181332-A1 PROTECTIVE OVERCOATS FOR THERMALLY DEVELOPABLE MATERIALS TROPHY DENTAL INC. 2009-07-16 US disclosed
US-7514206-B2 Thermally developable materials with buried conductive backside coatings CARESTREAM HEALTH, INC. (US) 2009-04-07 US disclosed
US-7468241-B1 Processing latitude stabilizers for photothermographic materials CARESTREAM HEALTH, INC. (US) 2008-12-23 US disclosed
WO-2008142295-A1 METHOD FOR OLIGOMERISING OLEFINS USING A CATALYTIC COMPOSITION COMPRISING AN ORGANOMETAL COMPLEX CONTAINING A PHENOXY LIGAND FUNCTIONALISED BY A HETEROATOM IFP (FR) 2008-11-27 WO disclosed
US-5171657-A Containing photopolymerizable monomer CANON KABUSHIKI KAISHA (JP) 1992-12-15 US disclosed
EP-0461621-A2 Image forming method CANON KABUSHIKI KAISHA (JP) 1991-12-18 EP disclosed
EP-0453125-A2 Image forming method and image forming apparatus CANON KABUSHIKI KAISHA (JP) 1991-10-23 EP disclosed
US-5021321-A Photothermography; antifogging agents; contrast; lamination of matrix of silver salts and reducing agent and dispersed particles of dye, polymer precursor and photoinitiator CANON KABUSHIKI KAISHA (JP) 1991-06-04 US disclosed
EP-0412851-A2 Photosensitive member and multi-color image forming method CANON KABUSHIKI KAISHA (JP) 1991-02-13 EP disclosed
EP-0363790-A2 Image forming method and image forming medium CANON KABUSHIKI KAISHA (JP) 1990-04-18 EP disclosed
US-4247427-A Adhesion promoted block copolyester composition with multi-functional carboxylic compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-01-27 US disclosed
US-4156702-A Adhesion promoted block copolyester composition with multi-functional carboxylic compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1979-05-29 US disclosed
US-4048128-A ALKALINE EARTH OXIDE, POLYCARBODIIMIDE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-09-13 US disclosed
US-3969294-A Segmented copolyester adhesives stabilized by alkaline earth oxides and carboxylic compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213190-A1 PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM HAO2, CPNE4, POF1B HSPA5 2892/4885CYP2C9 1199/4885CYP2C19 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.